Adherium Surges 30% in US Patient Growth, Raises $4.5M to Fuel Expansion

Strong Patient Growth Signals Market Traction

Adherium Limited (ASX – ADR), a leader in connected respiratory medical devices, has reported a significant 30% increase in active US commercial patients using its remote patient monitoring (RPM) platform, reaching approximately 1,500 users by the end of June 2025. This growth follows the implementation of new onboarding systems and targeted digital outreach campaigns that engaged over 24,000 patients, highlighting the company’s ability to scale its user base effectively within a competitive digital health landscape.

The company’s data-driven approach, focusing on high-conversion opportunities from a pipeline exceeding 100,000 potential RPM candidates, demonstrates a strategic emphasis on sustainable patient acquisition and retention. This momentum is further supported by ongoing collaborations with physician networks and value-based care programs, which are critical to expanding clinical adoption.

Capital Raise Strengthens Financial Flexibility

Adherium successfully closed an Accelerated Non-Renounceable Entitlement Offer (ANREO) in July 2025, raising $4.492 million, surpassing its initial $4 million target. The oversubscription and increased underwritten component underscore strong investor confidence, including commitments from Phillip Thematic Fund (Singapore) and sub-underwriters Bioscience Managers and Trudell Medical.

This capital injection arrives at a crucial time, as the company’s cash reserves were notably low at $43,000 at quarter-end, down from $684,000 the previous quarter. The fresh funds are earmarked for accelerating commercial scaling, enhancing onboarding infrastructure, and advancing product development, positioning Adherium to capitalize on its operational momentum.

Leadership and Strategic Partnerships Bolster Growth Prospects

July 2025 saw the appointment of Dawn Bitz as CEO, bringing nearly three decades of global leadership in medtech and digital health. Her track record in scaling innovative respiratory care businesses is expected to drive Adherium’s next phase of growth. Additionally, the board welcomed Keven Gessner, a seasoned pharmaceutical and digital health executive with expertise in market access and AI applications in healthcare.

Strategic partnerships continue to expand, notably with the Consortium of Independent Immunology Clinics (CIIC), which offers streamlined access to Adherium’s Hailie® Smartinhaler® platform across multiple practices. The ongoing Intermountain Health iCare program, now entering its second year, is anticipated to provide valuable clinical data later this year, potentially strengthening payer and provider engagement.

Outlook – Scaling and Data-Driven Optimization

Looking ahead, Adherium aims to scale onboarding campaigns with Allergy Partners and SENTA, deepen adoption within CIIC member practices, and optimize campaign performance through enhanced analytics. The company is also focused on managing the iCare study’s second year and leveraging forthcoming clinical outcomes to support broader market penetration.

While the recent capital raise alleviates immediate liquidity concerns, the company’s ability to sustain growth and convert clinical data into commercial success will be critical. Investors will be watching closely as Adherium navigates this pivotal growth phase under new leadership.